Recent News Releaseshttps://www.kitepharma.com/news/press-releases/rss-feedRecent News Releasesen{32E2C6A9-831F-4687-8609-4F3271953955}https://www.kitepharma.com/news/press-releases/2026/2/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-celGilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-celMon, 23 Feb 2026 11:01:00 Z{12272369-6B05-4998-8ED1-02F9B17CEADE}https://www.kitepharma.com/news/press-releases/2026/2/fda-approves-label-update-for-kites-yescarta-for-relapsedrefractory-primary-central-nervous-system-lymphomaFDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System LymphomaFri, 06 Feb 2026 13:30:00 Z{5813CD21-5A2A-490C-B671-4AC99E496326}https://www.kitepharma.com/news/press-releases/2025/12/yescarta-delivers-consistent-safety-efficacy-and-quality-of-life-benefits-across-broad-range-of-relapsedrefractory-large-bcell-lymphoma-patientsYescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025Sun, 07 Dec 2025 13:00:00 Z{EECA4FCA-BBE9-4F86-B140-1C042FB13287}https://www.kitepharma.com/news/press-releases/2025/12/kite-announces-new-data-for-pivotal-immagine1-study-at-ash-2025-highlighting-anitocels-opportunity-in-relapsed-or-refractory-multiple-myelomaKite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple MyelomaSat, 06 Dec 2025 19:00:00 Z{AD4317B1-D1BC-4EA6-A817-27AE5950FC55}https://www.kitepharma.com/news/press-releases/2025/12/kites-next-generation-bicistronic-car-t-cell-therapies-show-encouraging-phase-1-results-in-relapsedrefractory-b-cell-lymphoma-in-new-data-at-ash-202Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025Sat, 06 Dec 2025 19:00:00 Z{608758EC-976A-4A8F-8CB2-27FA7D0F63A0}https://www.kitepharma.com/news/press-releases/2025/11/gilead-and-kite-showcase-continued-progress-in-transforming-blood-cancer-care-with-new-cell-therapy-data-at-ash-2025Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025Mon, 03 Nov 2025 14:10:00 Z{A45EA2C8-4E15-4DA7-B441-DE4545A0DCC4}https://www.kitepharma.com/news/press-releases/2025/10/gilead-and-kite-reinforce-bold-commitment-to-transform-cancer-care-with-new-data-at-esmo-2025Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025Mon, 13 Oct 2025 12:30:00 Z{4776C241-8DD2-4343-8318-DCA135FBEBB9}https://www.kitepharma.com/news/press-releases/2025/8/kite-to-acquire-interius-biotherapeutics-to-advance-in-vivo-platformKite to Acquire Interius BioTherapeutics to Advance In Vivo PlatformThu, 21 Aug 2025 12:30:00 Z{5ACB9A5C-AE2B-4804-A705-7E07021F585E}https://www.kitepharma.com/news/press-releases/2025/6/kite-presents-new-real-world-data-supporting-use-of-potentially-curative-yescarta-in-outpatient-care-setting-for-patients-with-relapsedrefractory-laKite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025Sun, 01 Jun 2025 12:00:00 Z{B8D96494-CD7D-4247-9212-01E66FE69FDC}https://www.kitepharma.com/news/press-releases/2025/5/gilead-and-kite-announce-presentation-of-transformative-data-in-1l-metastatic-triplenegative-breast-cancer-updated-results-in-multiple-myeloma-and-eGilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHAThu, 15 May 2025 20:15:00 Z{7B29A357-1ED4-410F-8FAF-2CBC88680D0D}https://www.kitepharma.com/news/press-releases/2024/12/kites-yescarta-only-car-t-cell-therapy-to-show-durable-response-and-long-term-survival-after-five-years-in-patients-with-relapsedrefractory-non-hodKite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024Mon, 09 Dec 2024 22:45:00 Z{333F0569-FBCA-41A3-B75F-64D5E03EA6B2}https://www.kitepharma.com/news/press-releases/2024/12/longest-follow-up-data-reported-for-kites-tecartus-car-t-cell-therapy-at-ash-2024-reinforce-durable-efficacy-and-survival-benefitsLongest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival BenefitsMon, 09 Dec 2024 21:30:00 Z{B5087A5E-7ABC-40A2-B5E0-0F9D371DC60D}https://www.kitepharma.com/news/press-releases/2024/12/kite-presents-new-data-underscoring-curative-potential-of-yescarta-in-relapsedrefractory-large-b-cell-lymphoma-at-ashKite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASHSun, 08 Dec 2024 17:30:00 Z{8FF4E935-8B36-4688-99DC-3B9853C576D5}https://www.kitepharma.com/news/press-releases/2024/11/kite-to-highlight-industryleading-car-tcell-therapy-portfolio-at-ash-2024-including-positive-survival-outcomes-in-both-clinical-trials-and-the-realKite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-WorldTue, 05 Nov 2024 14:15:00 Z{95158CDF-4D34-4279-ABA4-D8D9DC973829}https://www.kitepharma.com/news/press-releases/2024/6/new-kite-clinical-research-and-real-world-evidence-for-yescarta-demonstrate-benefit-from-earlier-lines-of-treatmentNew Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of TreatmentFri, 14 Jun 2024 07:00:00 Z{18705EEB-F05B-49A0-8E14-E909ABC8045E}https://www.kitepharma.com/news/press-releases/2024/6/kites-tecartus-demonstrates-sustained-overall-survival-in-adult-patients-with-relapsedrefractory-b-cell-acute-lymphoblastic-leukemiaKite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaMon, 03 Jun 2024 14:00:00 Z{DF7DC006-F586-4A4A-8DFA-620EF7E233AB}https://www.kitepharma.com/news/press-releases/2024/6/encouraging-new-data-presented-on-kites-yescarta-for-relapsedrefractory-central-nervous-system-lymphomaEncouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System LymphomaMon, 03 Jun 2024 13:00:00 Z{2D5F8156-C346-4125-9481-8E7C84E48862}https://www.kitepharma.com/news/press-releases/2024/5/kite-data-at-eha-2024-demonstrate-positive-patient-outcomes-and-advances-in-delivery-of-car-t-cell-therapyKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyTue, 14 May 2024 14:09:00 Z{3CC5D5B3-7889-4E80-86BA-9922322C62BA}https://www.kitepharma.com/news/press-releases/2024/5/kite-and-arcellx-continue-momentum-with-advances-in-anito-cel-multiple-myeloma-programKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramThu, 09 May 2024 20:05:00 Z{BB42147F-C89E-436F-8FFB-60FA90E4F0DA}https://www.kitepharma.com/news/press-releases/2024/5/gilead-and-kite-oncology-to-highlight-broad-and-diverse-oncology-portfolio-at-asco-2024Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024Tue, 07 May 2024 12:30:00 Z{6A5B5D43-0B89-424E-B845-C156580D843E}https://www.kitepharma.com/news/press-releases/2024/1/kite-receives-us-fda-approval-of-manufacturing-process-change-resulting-in-reduced-median-turnaround-time-for-yescarta-car-tcell-therapyKite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell TherapyTue, 30 Jan 2024 13:30:00 Z{B1A9751D-B39F-4E23-A705-377D249B18C9}https://www.kitepharma.com/news/press-releases/2023/12/us-fda-approves-label-update-for-kites-yescarta-car-tcell-therapy-to-include-overall-survival-dataU.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival DataThu, 21 Dec 2023 21:05:00 Z{36BDBC45-8A88-4AA6-99F3-2E43F6AFD9EA}https://www.kitepharma.com/news/press-releases/2023/12/analyses-of-kites-yescartacar-t-cell-therapy-support-curative-potential-in-patients-with-non-hodgkin-lymphomasAnalyses of Kite’s Yescarta®CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin LymphomasTue, 12 Dec 2023 02:00:00 Z{1F7BB521-A343-4822-BF81-E35E8FB17741}https://www.kitepharma.com/news/press-releases/2023/12/new-analyses-presented-at-ash-2023-support-the-potential-long-term-response-and-safety-of-kites-tecartus-in-patients-with-aggressive-blood-cancersNew Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood CancersTue, 12 Dec 2023 00:30:00 Z{3F2A84E6-7669-4B86-82E5-A48C27596448}https://www.kitepharma.com/news/press-releases/2023/12/long-term-data-for-kites-yescarta-car-t-cell-therapy-presented-at-ash-2023-demonstrate-high-rate-of-durable-response-in-patients-with-high-risk-largLong-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell LymphomaMon, 11 Dec 2023 22:45:00 Z{1BF5E1FF-05EF-4FC7-A05D-B2C71A899166}https://www.kitepharma.com/news/press-releases/2023/11/kite-and-arcellx-announce-expansion-in-strategic-partnershipKite and Arcellx Announce Expansion in Strategic PartnershipWed, 15 Nov 2023 11:00:00 Z{A9B7C064-3776-4A59-92DB-306C9928B0AE}https://www.kitepharma.com/news/press-releases/2023/11/gilead-and-kite-oncology-present-data-demonstrating-car-t-cell-therapy-survival-benefit-and-showcasing-latest-advances-in-blood-cancer-portfolio-at-asGilead and Kite Oncology Present Data Demonstrating CAR T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023Thu, 02 Nov 2023 13:15:00 Z{00313906-19D3-4434-B556-45740EBD48BE}https://www.kitepharma.com/news/press-releases/2023/10/kite-and-epic-bio-announce-collaboration-to-develop-new-therapies-for-cancerKite and Epic Bio Announce Collaboration to Develop New Therapies for CancerTue, 31 Oct 2023 11:30:00 Z{3E9E7B8B-F56B-4AF1-A78F-CA87D3AF6016}https://www.kitepharma.com/news/press-releases/2023/10/gilead-and-kite-oncology-present-important-new-data-across-multiple-difficult-to-treat-cancers-at-esmo-congress-2023Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023Mon, 16 Oct 2023 11:30:00 Z{9394DF8B-CE3C-408A-9641-715C3EF0E7E7}https://www.kitepharma.com/news/press-releases/2023/9/kites-car-t-cell-therapy-yescarta-demonstrates-high-response-rate-and-durable-remission-in-alycante-study-as-initial-treatment-for-transplant-ineligKite’s CAR T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell LymphomaMon, 18 Sep 2023 08:00:00 Z{FBAF8F46-E529-4485-81D5-492F64A5757D}https://www.kitepharma.com/news/press-releases/2023/6/kite-announces-completion-of-marketing-authorization-transfer-for-yescarta-car-t-cell-therapy-in-japanKite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in JapanThu, 22 Jun 2023 12:30:00 Z{8BDB8B55-87D3-4F61-8400-B141DA9F8327}https://www.kitepharma.com/news/press-releases/2023/6/kites-tecartus-car-tcelltherapy-demonstrates-78-complete-response-rate-and-90-overall-response-rate-in-largest-realworld-evidence-analysis-for-rKite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell LymphomaTue, 06 Jun 2023 14:45:00 Z{D9E19627-C8B4-4D48-869D-270886FA0E6D}https://www.kitepharma.com/news/press-releases/2023/6/kites-yescarta-car-t-cell-therapy-demonstrates-significantly-longer-overall-survival-versus-standard-of-care-as-initial-treatment-of-relapsedrefracKite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell LymphomaMon, 05 Jun 2023 15:25:00 Z{E1ACE649-8A2A-45DE-BEA5-747F76B520CB}https://www.kitepharma.com/news/press-releases/2023/6/gilead-and-kite-oncology-demonstrate-growing-hematology-pipeline-and-strength-of-leading-cell-therapy-portfolio-at-ehaGilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHAThu, 01 Jun 2023 12:34:00 Z{F28B4977-1251-4502-AEB4-72FB6EF7122A}https://www.kitepharma.com/news/press-releases/2023/5/gilead-and-kite-oncology-to-showcase-advances-across-the-pipeline-aiming-to-address-unmet-needs-in-cancer-care-at-asco-2023Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023Wed, 17 May 2023 12:30:00 Z{160FBC9B-3BB2-42D5-B86C-A732B85C0189}https://www.kitepharma.com/news/press-releases/2023/5/gilead-appoints-cindy-perettie-executive-vice-president-of-kiteGilead Appoints Cindy Perettie Executive Vice President of KiteTue, 16 May 2023 20:01:00 Z{A698B452-98A5-4F40-88E8-4ECD8BA56202}https://www.kitepharma.com/news/press-releases/2023/3/kites-yescarta-car-t-cell-therapy-demonstrates-a-statistically-significant-improvement-in-overall-survival-for-initial-treatment-of-relapsedrefractKite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell LymphomaTue, 21 Mar 2023 13:37:00 Z{625A5096-52E0-4C0E-A3CF-E286AD905417}https://www.kitepharma.com/news/press-releases/2023/2/kite-completes-acquisition-of-tmunityKite Completes Acquisition of TmunityWed, 22 Feb 2023 14:00:00 Z{AFD5F258-9848-4781-839A-2A177F901D49}https://www.kitepharma.com/news/press-releases/2023/2/kites-tecartus-car-t-cell-therapy-demonstrates-overall-survival-benefit-in-three-year-follow-up-of-pivotal-zuma-3-trial-in-relapsedrefractory-b-celKite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaThu, 09 Feb 2023 12:15:00 Z{345D3092-240D-4D3E-8FCE-540D52003C50}https://www.kitepharma.com/news/press-releases/2023/2/gilead-sciences-announces-fourth-quarter-and-full-year-2022-financial-resultsGilead Sciences Announces Fourth Quarter and Full Year 2022 Financial ResultsThu, 02 Feb 2023 21:01:00 Z{41B3AA84-3BB8-47A3-BD6F-924CDF4E95E8}https://www.kitepharma.com/news/press-releases/2023/1/kite-and-arcellx-close-agreement-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myelomaKite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple MyelomaMon, 30 Jan 2023 14:00:00 Z{3BFF938C-F830-42B2-9ABB-CC443B8D2937}https://www.kitepharma.com/news/press-releases/2022/12/yescarta-now-approved-in-japan-for-initial-treatment-of-relapsedrefractory-large-b-cell-lymphomaYescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell LymphomaThu, 22 Dec 2022 21:30:00 Z{54D60003-741F-4C22-BD06-490C940B1CE0}https://www.kitepharma.com/news/press-releases/2022/12/kite-to-acquire-tmunity-therapeutics-to-pursue-next-generation-car-t-cell-therapy-advancements-in-cancerKite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in CancerTue, 20 Dec 2022 13:00:00 Z{3CE2B368-E591-4B72-AB85-2BACF61EE729}https://www.kitepharma.com/news/press-releases/2022/12/new-analyses-of-kites-tecartus-car-tcell-therapy-provide-additional-evidence-supporting-overall-survival-and-durability-of-responseNew Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of ResponseMon, 12 Dec 2022 15:00:00 Z{24B4344E-CBBA-4040-B9E3-096E64200330}https://www.kitepharma.com/news/press-releases/2022/12/threeyear-followup-analysis-of-kites-yescarta-car-tcell-therapy-zuma5-trial--52-of-patients-with-indolent-lymphomas-continued-to-have-ongoinThree-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 MonthsMon, 12 Dec 2022 15:00:00 Z{B67A3429-A894-45A9-8749-7286714F54D7}https://www.kitepharma.com/news/press-releases/2022/12/body-of-evidence-grows-from-zuma-7-study-supporting-initial-treatment-with-kites-yescarta-car-t-cell-therapy-for-patients-with-relapsed-or-refractorBody of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell LymphomaSun, 11 Dec 2022 22:30:00 Z{D73E6F28-1F78-423F-A823-8727DD630AF0}https://www.kitepharma.com/news/press-releases/2022/12/time-to-car-t-cell-therapy-may-impact-outcomes-for-patients-with-relapsedrefractory-large-b-cell-lymphoma-in-new-cibmtr-analysisTime to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR AnalysisSun, 11 Dec 2022 15:00:00 Z{ADF9A0EA-8CFC-44AE-9EFC-CA694F7A326F}https://www.kitepharma.com/news/press-releases/2022/12/kite-and-arcellx-announce-strategic-collaboration-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myelomaKite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple MyelomaFri, 09 Dec 2022 13:17:00 Z{BCF46D9A-0D7F-43FC-B7D5-F1F91C89C88A}https://www.kitepharma.com/news/press-releases/2022/12/kite-and-daiichi-sankyo-announce-changes-to-yescarta-car-t-cell-therapy-licensing-agreement-in-japanKite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in JapanWed, 07 Dec 2022 21:30:00 Z{41DA4942-6346-4047-B7A4-962152BB3B71}https://www.kitepharma.com/news/press-releases/2022/11/gilead-and-kite-oncology-demonstrate-transformative-impact-of-cell-therapy-and-promise-of-blood-cancer-portfolio-at-ash-2022Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022Thu, 03 Nov 2022 13:15:00 Z